Intestinal Infections https://greenmedinfo.com/taxonomy/term/40350/all en Proton pump inhibitors may increase the problem of intestinal bacterial overgrowth and irritable bowel syndrome. https://greenmedinfo.com/article/proton-pump-inhibitors-may-increase-problem-intestinal-bacterial-overgrowth-an PMID:  Am J Gastroenterol. 2008 Dec;103(12):2972-6. PMID: 19086951 Abstract Title:  Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors? Abstract:  Some studies indicate that small intestinal bacterial overgrowth (SIBO), as measured by hydrogen breath tests (HBT), is more prevalent in patients with irritable bowel syndrome (IBS) vs. matched controls without IBS. Although the data are conflicting, this observation has led to the hypothesis that SIBO may be a primary cause of IBS. Yet, it remains unclear whether SIBO is truly fundamental to the pathophysiology of IBS, or is instead a mere epiphenomenon or bystander of something else altogether. We hypothesize that SIBO might be a byproduct of the disproportionate use of proton pump inhibitors (PPIs) in IBS, as follows: (1) IBS patients are more likely than controls to receive PPI therapy; (2) PPI therapy may promote varying forms of SIBO by eliminating gastric acid; and (3) existing studies linking SIBO to IBS have not adjusted for or excluded the use of PPI therapy. When linked together, these premises form the basis for a simple and testable hypothesis: the relationship between SIBO and IBS may be confounded by PPIs. Our article explores these premises, lays out the argument supporting this "PPI hypothesis," discusses potential implications, and outlines next steps to further investigate this possibility. https://greenmedinfo.com/article/proton-pump-inhibitors-may-increase-problem-intestinal-bacterial-overgrowth-an#comments Intestinal Infections Irritable Bowel Syndrome Diseases that are Linked Human Study Wed, 27 Oct 2010 14:35:53 +0000 greenmedinfo 58180 at https://greenmedinfo.com There is an increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. https://greenmedinfo.com/article/there-increased-incidence-small-intestinal-bacterial-overgrowth-during-proton- PMID:  Clin Gastroenterol Hepatol. 2010 Jun;8(6):504-8. Epub 2010 Jan 6. PMID: 20060064 Abstract Title:  Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Abstract:  BACKGROUND&AIMS: Proton pump inhibitors (PPIs) can cause diarrhea, enteric infections, and alter the gastrointestinal bacterial population by suppressing the gastric acid barrier. Among patients that received long term PPI treatment, we evaluated the incidence of small intestinal bacterial overgrowth (SIBO; assessed by glucose hydrogen breath test [GHBT]), the risk factors for development of PPI-related SIBO and its clinical manifestations, and the eradication rate of SIBO after treatment with rifaximin. METHODS: GHBTs were given to 450 consecutive patients (200 with gastroesophageal reflux disease who received PPIs for a median of 36 months; 200 with irritable bowel syndrome [IBS], in absence of PPI treatment for at least 3 years; and 50 healthy control subjects that had not received PPI for at least 10 years). Each subject was given a symptoms questionnaire. RESULTS: SIBO was detected in 50% of patients using PPIs, 24.5% of patients with IBS, and 6% of healthy control subjects; there was a statistically significant difference between patients using PPIs and those with IBS or healthy control subjects (P https://greenmedinfo.com/article/there-increased-incidence-small-intestinal-bacterial-overgrowth-during-proton-#comments Intestinal Infections Immunosuppressive Human Study Wed, 27 Oct 2010 14:34:32 +0000 greenmedinfo 58179 at https://greenmedinfo.com